Clora

Is your biotech team structured for agility? With the biotech talent pool growing 50% over five years, independent consultants offer a flexible solution for critical, short-term needs. Our latest eBook dives into how consultants can bring specialized expertise to projects at key phases—without the long-term commitment. Discover how this approach can reduce fixed costs, improve time-to-hire, and support your R&D goals: https://ow.ly/cVZy50U85oP #Clora #biotech #consultants #futureofwork #lifesciences #talentacquisition

Antibody-drug conjugates (ADCs) are making waves in oncology, with recent clinical trial data showcasing their transformative potential. Merck, in collaboration with Daiichi Sankyo, announced that their HER3-directed ADC achieved its primary endpoint in a Phase 3 lung cancer study, marking a significant milestone on the path toward FDA approval. Similarly, BioNTech and DualityBio have shared promising early clinical data for their ADC candidates, further fueling excitement around this innovative therapeutic approach. Read more: https://ow.ly/xteU50UoGtN #Clora #lifesciences #clinicaltrials #oncology #lungcancer

Choosing the right talent model can make or break program timelines for biotechs. Many companies face a tough decision between hiring full-time employees, partnering with CROs, or leveraging consultants. Our new eBook details the pros and cons of each approach, from the agility of consultants to the deep resources of CROs, enabling leaders to choose the right talent mix to match their goals. Ready to streamline your hiring strategy for accelerated results? Get the eBook: https://ow.ly/78YK50U85iC #Clora #biotech #talent #consultants #lifesciences #staffingsolutions

Rahul Chaturvedi sits down with Kristin Yarema, Ph.D., President and CEO of Poseida Therapeutics, Inc., for an inspiring conversation about her journey from the lab bench to the C-suite. Kristin shares her transition from science to leadership roles in big pharma, pivotal experiences at Novartis and Amgen, her passion for advancing oncology and autoimmune research, and her bold leap into biotech entrepreneurship and cell therapy innovation. Listen to the episode now using the link below. #Clora #biotech #podcast #leadership #oncology #celltherapy #innovation

The obesity treatment sector is experiencing unprecedented growth, highlighted by Metsera's $215 million Series B funding, bringing its total capital raised to over $500 million since April: https://ow.ly/c3Xp50UcXZZ This investment surge is reflected in major funding rounds for companies like BioAge Labs, Kailera Therapeutics, OrsoBio, Hercules CM, SixPeaks Bio, and more. Reflecting this momentum, Morgan Stanley has adjusted its forecast, projecting the global obesity drug market to reach $105 billion by 2030, up from an earlier estimate of $77 billion. As the industry expands, Clora is dedicated to empowering life science companies to accelerate breakthroughs by connecting them with the on-demand expertise needed to drive progress in obesity treatment and beyond. #Clora #biotech #obesity #lifesciences #investment

Join Rahul Chaturvedi for a conversation with Bharatt Chowrira, CEO, and Eric Elenko, Co-Founder & President, of PureTech Health, on a new episode of Biotech2050. Bharatt and Eric dive deep into PureTech’s R&D model—one that prioritizes solving specific problems over traditional approaches. They share their professional journeys, emphasizing the power of simplicity, persistence, and patient-centered innovation. The discussion includes a look at the rise of Karuna Therapeutics, a PureTech-founded company, and its journey to developing a transformative schizophrenia treatment. Tune in for valuable insights into the future of drug development, the need for more efficient pathways, and an exciting glimpse at what’s next for PureTech. #Clora #biotech #podcast #drugdevelopment #innovation #schizophrenia

With only 48% of essential roles being filled and full-time hiring taking over 105 days, programs for many biotech organizations are facing costly delays. Our latest eBook explores strategic alternatives to overcome these hurdles for the biotech industry. Learn about flexible options that can help you scale faster and meet milestones on time. Download the eBook now to find the ideal staffing solutions for your organization: https://ow.ly/Sh8l50U859o #Clora #biotech #hiring #talent #lifesciences #eBook

Preclinical-stage Septerna’s recent IPO, raising an impressive $288M in the absence of clinical data, is a strong signal that the biotech investment market is heating up. This IPO, which exceeded expectations, follows other successful public offerings by Zenas BioPharma, MBX Biosciences, Inc., and Bicara Therapeutics—all early-stage biotech companies performing well on the public market. Investor confidence seems to be returning, with renewed interest in supporting innovative biotech firms at earlier development phases. This momentum could open up more opportunities for companies pushing the boundaries in research to bring forward new solutions in healthcare. More here: https://ow.ly/2s7W50U5uat #Clora #biotech #investment #IPO #innovation #healthcare

We're excited to share the latest episode of Biotech2050, hosted by Clora's own Rahul Chaturvedi. This time, he's joined by Robert Williamson, CEO of Triumvira Immunologics, Inc. Rob shares his journey from economics to biotech and the unique insights he's gained tackling the high-stakes world of cell therapy. With topics spanning therapeutic advancements, the demands of solid tumor research, and strategies for managing biotech board dynamics, Rob sheds light on key challenges and opportunities in the life sciences landscape. Don’t miss his expert take on navigating today’s volatile capital markets and the emerging role of AI in healthcare. Tune in using the link below. #Clora #biotech #podcast #celltherapy #lifesciences #AI #healthcare

Rahul Chaturvedi sits down with Gene Mack, Interim CEO and CFO of Gain Therapeutics, for an insightful conversation about his career journey and unique perspectives on neurodegenerative diseases and the biotech industry. Gene shares how his path evolved from an initial goal of becoming a neurosurgeon, to a career in finance on Wall Street, and ultimately to a leadership role in biotech, where he now drives critical advancements in neurodegenerative disease research. Gene discusses Gain Therapeutics' promising approach to treating Parkinson's disease through GT02287, a lead asset aimed at modifying the disease itself rather than simply managing symptoms. Listen to their conversation now using the link below. #Clora #biotech #podcast #leadership #neurodegenerativedisease #Parkinsonsdisease